Manatt Health Senior Advisor Ian Spatz and Partner Alex Dworkowitz were quoted in InsuranceNewsNet on Manatt’s August 23 webinar, “Preparing for Change: A Guide to the Inflation Reduction Act Drug Pricing Provisions.”
The article highlighted the webinar’s primary points of discussion, including how drug manufacturers can navigate negotiations with the U.S. Department of Health and Human Services (HHS) for the cost of prescription drugs covered under Medicare Part D. Spatz noted that there is no judicial review of actions HHS may take regarding these negotiations. “No judicial review leads to questions – what if HHS doesn’t follow the rules as laid out? It’s not clear whether anyone can challenge their decisions not to follow the law exactly as it is written.”
Inflation rebates are another pillar of the IRA regarding prescription drugs and Medicare, said Dworkowitz. Manufacturers must pay rebates to the Supplemental Medical Insurance trust fund if they increase the price of their Medicare Part B and Part D drugs faster than the rate of inflation, and are subject to civil monetary penalties for failure to pay these rebates.
Read the full article here.